NuProbe Announces Strategic Collaboration with QIAGEN, Completes Multiple CE IVD Product Registrations

By All News, Strategic Collaborations

NuProbe and QIAGEN will collaborate to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy. NuProbe and QIAGEN will explore integrating their two amplicon-based enrichment and sequencing technologies: NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology and QIAGEN’s Single Primer Extension (SPE) technology,

Read More

NuProbe Announces Licensing Deal with Oxford Nanopore

By All News, Strategic Collaborations

Oxford Nanopore has licensed NuProbe’s Blocker Displacement Amplification technology globally for undisclosed consideration. The technology combination offers the potential to combine Oxford Nanopore sequencing, which offers real-time, rapid turnaround, scalable sequencing of any length DNA or RNA fragments, with the NuProbe technique to enable greater detection sensitivities and quantification of somatic mutations at less than 5% allele frequency.

Read More

    Request A Quote









    X